{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:08:05Z","timestamp":1764079685108},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,26]]},"DOI":"10.7759\/cureus.16644","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T19:17:35Z","timestamp":1627327055000},"source":"Crossref","is-referenced-by-count":4,"title":["The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders"],"prefix":"10.7759","author":[{"given":"Saswata","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipanjan","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrajit","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Joy Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Dementia. (2021). Accessed. June 12, 2021: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane CA","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018, 25:59-70. 10.1111\/ene.13439","journal-title":"Eur J Neurol"},{"key":"ref3","article-title":"World Alzheimer Report 2020 - Design, Dignity, Dementia: Dementia-Related Design and the Built Environment, Volume 1","author":"Fleming R","year":"2020","unstructured":"Fleming R, Zeisel J, Bennett K. World Alzheimer Report 2020 - Design, Dignity, Dementia: Dementia-Related Design and the Built Environment, Volume 1. Alzheimer\u2019s Disease International, London, England; 2020."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000109800","article-title":"Epidemiology of vascular dementia","volume":"14","author":"H\u00e9bert R","year":"1995","unstructured":"H\u00e9bert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology. 1995, 14:240-257. 10.1159\/000109800","journal-title":"Neuroepidemiology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer's disease facts and figures","volume":"17","year":"2021","unstructured":"2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021, 17.327-406. 10.1002\/alz.12328","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8682","article-title":"Neuroimaging in dementia: a brief review","volume":"12","author":"Banerjee D","year":"2020","unstructured":"Banerjee D, Muralidharan A, Hakim Mohammed AR, Malik BH. Neuroimaging in dementia: a brief review. Cureus. 2020, 12:e8682. 10.7759\/cureus.8682","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/1521654032000114348","article-title":"The neuropathological spectrum of neurodegenerative tauopathies","volume":"55","author":"Tolnay M","year":"2003","unstructured":"Tolnay M, Probst A. The neuropathological spectrum of neurodegenerative tauopathies. IUBMB Life. 2003, 55:299-305. 10.1080\/1521654032000114348","journal-title":"IUBMB Life"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2004.06.020","article-title":"Tau protein as a differential biomarker of tauopathies","volume":"1739","author":"Sergeant N","year":"2005","unstructured":"Sergeant N, Delacourte A, Bu\u00e9e L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta. 2005, 1739:179-197. 10.1016\/j.bbadis.2004.06.020","journal-title":"Biochim Biophys Acta"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.9b00326","article-title":"Identification of AV-1451 as a weak, nonselective inhibitor of monoamine oxidase","volume":"10","author":"Drake LR","year":"2019","unstructured":"Drake LR, Pham JM, Desmond TJ, et al.. Identification of AV-1451 as a weak, nonselective inhibitor of monoamine oxidase. ACS Chem Neurosci. 2019, 10:3839-3846. 10.1021\/acschemneuro.9b00326","journal-title":"ACS Chem Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Bu\u00e9e L","year":"2000","unstructured":"Bu\u00e9e L, Bussi\u00e8re T, Bu\u00e9e-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000, 33:95-130. 10.1016\/S0165-0173(00)00019-9","journal-title":"Brain Res Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer's disease","volume":"12","author":"Martin L","year":"2013","unstructured":"Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev. 2013, 12:289-309. 10.1016\/j.arr.2012.06.003","journal-title":"Ageing Res Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy J","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297:353-356. 10.1126\/science.1072994","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww340","article-title":"18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy","volume":"140","author":"Passamonti L","year":"2017","unstructured":"Passamonti L, V\u00e1zquez Rodr\u00edguez P, Hong YT, et al.. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain. 2017, 140:781-791. 10.1093\/brain\/aww340","journal-title":"Brain"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa276","article-title":"18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases","volume":"143","author":"Soleimani-Meigooni DN","year":"2020","unstructured":"Soleimani-Meigooni DN, Iaccarino L, La Joie R, et al.. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain. 2020, 143:3477-3494. 10.1093\/brain\/awaa276","journal-title":"Brain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele R","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, et al.. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016, 139:1551-1567. 10.1093\/brain\/aww027","journal-title":"Brain"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx353","article-title":"Networks of tau distribution in Alzheimer's disease","volume":"141","author":"Hoenig MC","year":"2018","unstructured":"Hoenig MC, Bischof GN, Seemiller J, et al.. Networks of tau distribution in Alzheimer's disease. Brain. 2018, 141:568-581. 10.1093\/brain\/awx353","journal-title":"Brain"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx328","article-title":"Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies","volume":"141","author":"Forrest SL","year":"2018","unstructured":"Forrest SL, Kril JJ, Stevens CH, et al.. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain. 2018, 141:521-534. 10.1093\/brain\/awx328","journal-title":"Brain"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0470-7","article-title":"18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes","volume":"11","author":"Tsai RM","year":"2019","unstructured":"Tsai RM, Bejanin A, Lesman-Segev O, et al.. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019, 11:13. 10.1186\/s13195-019-0470-7","journal-title":"Alzheimers Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.366","article-title":"[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation","volume":"3","author":"Bevan Jones WR","year":"2016","unstructured":"Bevan Jones WR, Cope TE, Passamonti L, et al.. [18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Ann Clin Transl Neurol. 2016, 3:940-947. 10.1002\/acn3.366","journal-title":"Ann Clin Transl Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww163","article-title":"18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers","volume":"139","author":"Smith R","year":"2016","unstructured":"Smith R, Puschmann A, Sch\u00f6ll M, et al.. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016, 139:2372-2379. 10.1093\/brain\/aww163","journal-title":"Brain"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316402","article-title":"[18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia","volume":"89","author":"Bevan-Jones WR","year":"2018","unstructured":"Bevan-Jones WR, Cope TE, Jones PS, et al.. [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018, 89:1032-1037. 10.1136\/jnnp-2017-316402","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24825","article-title":"AV-1451 tau and \u03b2-amyloid positron emission tomography imaging in dementia with Lewy bodies","volume":"81","author":"Kantarci K","year":"2017","unstructured":"Kantarci K, Lowe VJ, Boeve BF, et al.. AV-1451 tau and \u03b2-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017, 81:58-67. 10.1002\/ana.24825","journal-title":"Ann Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.3338","article-title":"Tau positron emission tomographic imaging in the Lewy body diseases","volume":"73","author":"Gomperts SN","year":"2016","unstructured":"Gomperts SN, Locascio JJ, Makaretz SJ, et al.. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 2016, 73:1334-1341. 10.1001\/jamaneurol.2016.3338","journal-title":"JAMA Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15694","article-title":"Neuroimaging in dementia with Lewy bodies","volume":"13","author":"Saha A","year":"2021","unstructured":"Saha A, Banerjee D. Neuroimaging in dementia with Lewy bodies. Cureus. 2021, 13:e15694. 10.7759\/cureus.15694","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23041-x","article-title":"18F-AV-1451 in Parkinson's disease with and without dementia and in dementia with Lewy bodies","volume":"8","author":"Smith R","year":"2018","unstructured":"Smith R, Sch\u00f6ll M, Londos E, Ohlsson T, Hansson O. 18F-AV-1451 in Parkinson's disease with and without dementia and in dementia with Lewy bodies. Sci Rep. 2018, 8:4717. 10.1038\/s41598-018-23041-x","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww098","article-title":"In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET","volume":"139","author":"Hansen AK","year":"2016","unstructured":"Hansen AK, Knudsen K, Lillethorup TP, et al.. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. Brain. 2016, 139:2039-2049. 10.1093\/brain\/aww098","journal-title":"Brain"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-017-1507-y","article-title":"[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP","volume":"223","author":"Coakeley S","year":"2018","unstructured":"Coakeley S, Cho SS, Koshimori Y, et al.. [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Struct Funct. 2018, 223:589-595. 10.1007\/s00429-017-1507-y","journal-title":"Brain Struct Funct"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26844","article-title":"Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho H","year":"2017","unstructured":"Cho H, Choi JY, Hwang MS, Lee SH, Ryu YH, Lee MS, Lyoo CH. Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017, 32:134-140. 10.1002\/mds.26844","journal-title":"Mov Disord"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26961","article-title":"In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography","volume":"32","author":"Hansen AK","year":"2017","unstructured":"Hansen AK, Damholdt MF, Fedorova TD, et al.. In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. Mov Disord. 2017, 32:922-927. 10.1002\/mds.26961","journal-title":"Mov Disord"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe VJ","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, et al.. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016, 4:58. 10.1186\/s40478-016-0315-6","journal-title":"Acta Neuropathol Commun"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marqui\u00e9 M","year":"2015","unstructured":"Marqui\u00e9 M, Normandin MD, Vanderburg CR, et al.. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015, 78:787-800. 10.1002\/ana.24517","journal-title":"Ann Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/63850-the-role-of-18f-flortaucipir-av-1451-in-the-diagnosis-of-neurodegenerative-disorders","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:07Z","timestamp":1707506887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/63850-the-role-of-18f-flortaucipir-av-1451-in-the-diagnosis-of-neurodegenerative-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.16644","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,26]]}}}